Mainz Biomed’s (MYNZ) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Mainz Biomed (NASDAQ:MYNZ)‘s stock had its “neutral” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports.

Separately, HC Wainwright dropped their price objective on shares of Mainz Biomed from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, March 6th.

Mainz Biomed Stock Performance

Shares of MYNZ stock opened at $0.97 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.93 and a current ratio of 0.97. Mainz Biomed has a one year low of $0.85 and a one year high of $6.10. The company’s 50-day simple moving average is $1.01 and its 200-day simple moving average is $1.40. The stock has a market capitalization of $11.65 million, a price-to-earnings ratio of -0.59 and a beta of 0.24.

Institutional Investors Weigh In On Mainz Biomed

Several institutional investors and hedge funds have recently bought and sold shares of the business. Prelude Capital Management LLC acquired a new stake in shares of Mainz Biomed in the fourth quarter valued at approximately $87,000. Citadel Advisors LLC acquired a new stake in shares of Mainz Biomed in the fourth quarter valued at approximately $39,000. Finally, Northern Trust Corp acquired a new stake in shares of Mainz Biomed in the fourth quarter valued at approximately $38,000.

Mainz Biomed Company Profile

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test.